CurifyLabs, a Finnish healthtech startup reinventing the way personalized medicines are produced in pharmacies, has raised $7,594,115 (€7 million) in a funding round led by Springvest and Business Finland.

Founded by Charlotta Topelius and Niklas Sandler, the company is solving a widespread but often overlooked challenge in healthcare: the need for safe, precise, and scalable drug compounding for patients who can’t rely on mass-manufactured medication.

Whether it’s a child needing a lower dose, a cancer patient requiring tailored treatment, or a person with allergies to standard pill ingredients - personalized medicine is essential, but logistically outdated. CurifyLabs is building the tools to change that.

---

What CurifyLabs Does

CurifyLabs is developing automated drug compounding technology, including 3D printing systems, to help pharmacies and hospitals create tailored medications on-site - safely, consistently, and efficiently.

Their technology stack includes:

• CurifyKit™, a modular 3D printing system for active pharmaceutical ingredient (API) compounding
  
• CurifyBase™, a library of printable, biocompatible pharmaceutical materials
  
• Quality assurance software with integrated Good Manufacturing Practice (GMP) compliance
  
• Custom workflows designed for pharmacy-level production
  

This approach streamlines drug formulation and dramatically reduces the risk of human error, which remains a critical concern in traditional compounding.

The result? Personalized medicines produced with industrial-level precision - right where they’re needed.

---

Why This Problem Matters

Despite incredible advances in pharmaceutical science, millions of patients still rely on manually compounded medications - often mixed in back rooms with minimal automation or oversight.

• An estimated 13 million prescriptions in the EU each year require compounding because off-the-shelf options don’t fit a patient’s dosage, delivery method, or allergen profile
  
• In the U.S., more than 7,500 compounding pharmacies operate, but face rising pressure from the FDA for better traceability and consistency
  
• Manual compounding is time-consuming and error-prone, with studies showing compounding error rates between 5–15% depending on the formulation
  
• In pediatric oncology alone, nearly 90% of patients require dose-adapted formulations that are rarely available from standard suppliers
  
• According to WHO, personalized medicine is a top-5 healthcare priority for the next decade - but delivery infrastructure remains decades behind
  

CurifyLabs is filling that gap with the hardware, software, and regulatory alignment to bring personalized medicine into the 21st century.

---

Why This Raise Matters

CurifyLabs isn’t just modernizing compounding - it’s creating a blueprint for distributed pharmaceutical manufacturing that gives individual pharmacies the power to act like micro-factories.

And this is where the strategic insight for founders becomes clear.

Ultra Value Drop: If your product transforms infrastructure, the key isn’t replacing existing systems - it’s reassigning capability to the edge.

CurifyLabs could’ve targeted large pharmaceutical companies and centralized manufacturing hubs. But instead, they saw something more scalable: give frontline pharmacists the tools to solve last-mile problems with industrial precision.

This is the big shift founders often miss. Real disruption doesn’t always look like toppling incumbents. Sometimes it looks like empowering overlooked players with better tools. Not everyone needs to own the supply chain - sometimes the win is in giving others the ability to produce with autonomy, accuracy, and speed.

CurifyLabs didn’t just automate an old process. They reframed who should have access to that process - and what happens when that access becomes standard.

---

Market Outlook: Personalized Drug Compounding is Entering a New Era

As medicine shifts toward personalization, the infrastructure that delivers it is being forced to evolve. Traditional “blockbuster” drug models - built around mass production - are increasingly incompatible with patient-specific needs. CurifyLabs is emerging at the forefront of this shift.

The numbers tell the story:

• The global personalized medicine market is projected to grow from $538 billion in 2023 to $922 billion by 2030, driven by advances in diagnostics, genomics, and targeted therapies (Market Research Future).
  
• The compounding pharmacy market is expected to grow at a CAGR of 6.1%, reaching $18.7 billion by 2028, fueled by demand for non-standard dosages, allergen-free medications, and pediatric formulations (Fortune Business Insights).
  
• According to the European Association of Hospital Pharmacists, up to 20% of hospital patients in the EU require customized drug formulations not commercially available.
  
• The 3D printing in pharmaceuticals market is forecasted to surpass $1.2 billion by 2030, with hospitals and pharmacies driving early adoption of on-demand, localized manufacturing (Allied Market Research).
  
• Regulatory bodies including the FDA and EMA are actively investing in frameworks to support automated compounding and digital quality assurance, citing improved traceability and reduced human error as key drivers.
  

Moreover, global shortages in drug supply chains have underscored the value of on-site, flexible manufacturing capabilities - especially in oncology, pediatrics, geriatrics, and rare diseases, where personalized care isn’t optional.

By enabling pharmacists to produce high-quality, individualized medications at the point of care, CurifyLabs is poised to become an essential link in the decentralized, precision-driven healthcare ecosystem of the future.

---

What’s Next for CurifyLabs?

With $7.6 million in new funding, CurifyLabs plans to scale its compounding platform to new pharmacy environments across Europe and eventually North America.

Key next steps include:

• Piloting 3D printing systems with select hospital pharmacies and academic medical centers
  
• Expanding compatibility with more APIs and personalized formulations for oncology, pediatrics, and rare diseases
  
• Strengthening partnerships with regulatory bodies and pharmaceutical suppliers to ensure GMP-aligned delivery at scale
  
• Hiring across regulatory, automation engineering, and product development to accelerate time to market
  
• Exploring strategic collaborations in pharma R&D and digital therapeutics, where personalized delivery could drive new breakthroughs
  

The long-term vision? A future where customized medication isn’t an exception - it’s the norm. And CurifyLabs is building the tools to make that future printable.

Let me know if you’d like this delivered as a press-ready format, pitch copy, LinkedIn carousel draft, or Webflow-ready CMS version.